PIH26 COST EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS AMONG EXTREME PRETERM INFANTS (29 WEEKS OF GESTATIONAL AGE) AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)
Abstract
Authors
J.Á. Paladio Hernández J.I. Lagunas-Quiroz N.A. Matías-Juan